医学
尿路上皮癌
成纤维细胞生长因子受体
尿路上皮癌
癌症研究
癌
肿瘤科
泌尿科
内科学
膀胱癌
成纤维细胞生长因子
癌症
受体
作者
Roger Li,Joshua A. Linscott,James W.F. Catto,Siamak Daneshmand,Bishoy M. Faltas,Ashish M. Kamat,Joshua J. Meeks,Andrea Necchi,Benjamin Pradere,Jeffrey S. Ross,Michiel S. van der Heijden,Bas W.G. van Rhijn,Yohann Loriot
标识
DOI：10.1016/j.eururo.2024.09.012
摘要
The 2024 US Food and Drug Administration approval of erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations ushered in the era of targeted therapy for bladder cancer. In this review, we summarize the effects of FGFR pathway alterations in oncogenesis, clinical data supporting FGFR inhibitors in the management of bladder cancer, and the challenges that remain.
科研通智能强力驱动
Strongly Powered by AbleSci AI
带头大哥
HEIKU
爱静静
彭于彦祖
寻道图强
Billy
平常的毛豆
xjcy
子车茗
Yziii
yangguang2000
马大翔
杳鸢
Lloyd_Lee
tuanheqi
iNk
mhl11
双黄
WLWLW
嗯哼
皖公网安备34019202002308
